Promise Details
On October 10, 2025, President Trump announced a drug-pricing agreement with AstraZeneca under which certain drugs would be offered to Medicaid at discounted MFN (Most-Favored-Nation) rates. Under the deal, AstraZeneca commits to list those medicines via the forthcoming TrumpRx portal with steep discounts in exchange for tariff relief for a specified period. The goal is to reduce costs for low-income Americans and press other pharmaceutical companies to follow suit. Though this aligns with his broader drug pricing agenda, the scope is currently limited to selected drugs and Medicaid. Broader application to private insurance, full MFN across all drugs, and long-term legislative backing remain to be seen.
What was done
AstraZeneca agreed to provide selected medications under MFN-style pricing arrangements for Medicaid recipients, fulfilling the specific commitment announced by the administration.
Sources
The information presented in this promise is aggregated from various publicly available sources. We do not claim ownership or guarantee the accuracy of the content. All data is collected and cross-validated from multiple independent sources. To read more about this promise, please view the source links below:
Support Our Work
Help us keep the website running and free for everyone by supporting us:
